<

Functional Abdominal Pain (FAP)

Two trials with Lactobacillus reuteri Protectis (BioGaia) have shown it to have a positive effect on those suffering from FAP.

Of course, not all strains of probiotics are equal; different strains have different properties and effects. Lactobacillus reuteri Protectis is a powerful strain that colonizes the entire gastrointestinal (GI) tract.

BioGaia Protectis supports the GI tract

  • Supports gastric emptying and improves GI motility

  • Can help to reduce the frequency and severity of pain

  • May improve gastric mucosal integrity

  • Promote overall digestive health in children and adults

  • Healthy bacterial balance in the digestive tract in balance contribute to gut comfort and overall wellbeing.

BioGaia Probiotic Tablets

Lactobacillus reuteri Protectis has been shown to promote healthy digestive health and function.

BioGaia Dosage recommendations

One chewable tablet or 5 drops a day.

Double blind study

Lactobacillus reuteri Protectis (DSM 17938) vs placebo in children with functional abdominal pain.

Weizman Z., Blumin V. Abu-Abed J., Binsztok M.: J Pediatr. 2016:174:160-164.

Results

  • Significant relief in frequency (p<0.02) and severity (p<0.01) of abdominal pain compared to placebo at 4 weeks.

  • Continuously and significantly relieved severity of abdominal pain compared to placebo at 8 weeks.

  • Reduced incidence of perceived abdominal distension and bloating compared to placebo at 4 weeks (p=0.013).

Conclusions

  • Demostrates that L. reuteri Protectis was effective in treating functional abdominal pain in children.

  • L. reuteri Protectis significantly reduced the frequency and severity of functional abdominal pain in children

Facts

  • Double blind, placebo-controlled study

  • 93 children aged 6-15 years with functional abdominal pain (Rome III criteria)

  • One chewable tablet Lactobacillus reuteri Protectis (BioGaia) 108 CFU/day daily (n=47) or placebo (n=46) for 4 weeks with follow-up of additional 4 weeks

RCT study

Lactobacillus reuteri Protectis (DSM 17938) in the treatment of functional abdominal pain in children.

Jadrešin O, Hojsak I, Mišak Z, Kekez AJ, Trbojević T, Ivković L, Kolaček S.
J Pediatr Gastroenterol Nutr. online 30 Nov 2016. doi: 10.1097/MPG.0000000000001478

Results

  • Significantly more pain-free days compared to placebo: 80% vs. 46% (p<0.05)
  • Both groups showed significant reduction in severity of pain compared to baseline
  • Retained effect on severity of pain. by L. reuteri Protectis during the follow-up month
  • First study to suggest that L. reuteri Protectis may be effective in children with IBS

Conclusions

  • Demonstrates that L. reuteri Protectis was effective in treating functional abdominal pain in childran

  • L. reuteri Protectis significantly reduced the number of days with pain and had a retained effect on severity of pain after supplementation of the study product had ended.

Facts

  • Double blind, placebo-controlled study
  • 55 children aged 4-18 years with functional abdominal pain or irritable bowel syndrome (Rome III criteria)
  • One chewable tablet Lactobacillus reuteri Protectis (BioGaia) 108 CFU/day daily (n=26) or placebo (n=29) for 12 weeks of intervention with follow-up of additional 4 weeks
We use cookies to make your experience of our website better.
Using this website means you are OK with this. Find out more.
OK